Maynard Um
-
-
-
-
-
-
-
Insulet Corporation (PODD) PT Lowered to $179 at Canaccord
-
-
-
-
-
-
-
UBS Assumes Insulet Corporation (PODD) at Neutral
-
-
-
-
-
-
-
Insulet reports positive trial data for next-generation diabetes systems
-
-
-
-
-
-
-
RBC sees over 80% upside to its price target for this medical stock
-
-
-
-
-
-
-
Insulet begins pivotal trial for fully closed-loop diabetes system
-
-
-
-
-
-
-
Insulet Corporation (PODD) PT Lowered to $330 at Bernstein
-
-
-
-
-
-
-
Barclays Downgrades Insulet Corporation (PODD) to Underweight
-
464,960 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


